Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 is a new market research publication announced by Reportstack. This report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies.
Revised and updated 12th edition, includes:
Trends in co-promotion and co-marketing deals
Co-promotion and co-marketing agreement structure
Co-promotion and co-marketing contract documents
Top co-promotion deals by value
Top co-marketing deals by value
Most active co-promotion dealmakers
Most active co-marketing dealmakers
This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.
To access full report with TOC, please visit Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015.
Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2010 to mid 2015.
The report provides a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all co-promotion and co-marketing deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 report is intended to provide the reader with an in-depth understanding of the co-promotion and co-marketing trends and structure of deals entered into by leading biopharma companies worldwide.
Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 includes:
Trends in co-promotion and co-marketing dealmaking in the biopharma industry since 2010
Analysis of co-promotion and co-marketing deal structure
Case studies of real-life co-promotion and co-marketing deals
Access to over 800 co-promotion and co-marketing deal records
Detailed access to actual co-promotion contract documents
The leading co-promotion and co-marketing deals by value since 2010
Most active co-promotion and co-marketing dealmakers since 2010
The leading co-promotion and co-marketing partnering resources
In Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015, the available contracts are listed by:
Stage of development at signing
TheGlobal Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 report provides comprehensive access to records for over 700 co-promotion and co-marketing deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise co-promotion and co-marketing rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law
Manager - Marketing
Reportstack Market Research